---
schema_version: "secwatch.filing_event.v1"
accession: "0001490978-23-000095"
form_type: "8-K/A"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:54:36.190396+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q2 revenue falls 8.5% to $35.2M; raises software guidance, cuts drug discovery outlook

## Summary
- GAAP net income of $4.3M vs loss of $47.7M; non-GAAP net loss widened to $56.8M from $43.8M.
- Total revenue $35.2M, down 8.5% YoY; drug discovery revenue fell 31% to $5.8M.
- 2023 software revenue growth guidance raised to 15-18%; drug discovery revenue guidance cut to $50-70M from $70-90M.
- IND cleared for CDC7 inhibitor SGR-2921; Phase 1 trial in AML/MDS planned for 2023.
- Margaret Dugan appointed CMO; Zai Lab collaboration not advanced, program wholly-owned.

## SEC filing metadata
- accession: 0001490978-23-000095
- form_type: 8-K/A
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000095/0001490978-23-000095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000095/sdgr-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001490978-23-000095
- JSON: https://secwatch.observer/filing/0001490978-23-000095.json
- Plain text: https://secwatch.observer/filing/0001490978-23-000095.txt

## Key facts
- Earnings Releases
  Schrodinger, Inc. reported second quarter ended June 30, 2023 results: revenue $35.2 million, net income $4.3 million. Guidance raised.
  - Period: second quarter ended June 30, 2023
  - Revenue: $35.2 million
  - Net income: $4.3 million
  - Guidance: raised
  - Result: reported results
  source text: Quarter 2023 Financial Results Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance New York, August 2, 2023 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform
  evidence_url: https://www.sec.gov/Archives/edgar/data/1490978/000149097823000095/0001490978-23-000095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.